Results 141 to 150 of about 19,757 (238)

Predicting Response to Pro‐Cognitive Interventions in Mood Disorders: A Systematic Review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 374-401, May 2026.
ABSTRACT Introduction Major depressive disorder (MDD) and bipolar disorder (BD) are often associated with persistent cognitive deficits that impair psychosocial functioning. While pro‐cognitive interventions show promise, trial findings are inconsistent, potentially due to baseline factors influencing treatment response.
Dimosthenis Tsapekos, Michail Kalfas, Johanna M. Schandorff, Caterina del Mar Bonnin, Christopher R. Bowie, Vicent Balanzá‐Martínez, Katherine E. Burdick, Andre F. Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Gregor Hasler, Lars V. Kessing, Hanne L. Kjærstad, Beny Lafer, Kathryn E. Lewandowski, Carlos López‐Jaramillo, Anabel Martinez‐Aran, Roger S. McIntyre, Richard J. Porter, Scot E. Purdon, Ayal Schaffer, Paul R. A. Stokes, Tomiki Sumiyoshi, Ivan J. Torres, Tamsyn E. Van Rheenen, Lakshmi N. Yatham, Jeff Zarp, Allan H. Young, Eduard Vieta, Kamilla W. Miskowiak   +30 more
wiley   +1 more source

Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy. [PDF]

Front Neurol
Sun Y, Song B, Zhang Y, Zhang Y, Zhou L.
europepmc   +1 more source

Downregulation of EPAS1 and EGLN1 mRNA Expression Associated With High‐Altitude Adaptive Genetic Variants in Sherpa Highlanders

Annals of Human Genetics, Volume 90, Issue 3, Page 202-214, May 2026.
ABSTRACT Background and Aims Sherpa highlanders exhibit remarkable tolerance to hypoxia, most likely due to genetic adaptations shaped by natural selection at high altitude. This study examined the roles of endothelial PAS domain protein 1 (EPAS1) and egl‐9 family hypoxia‐inducible factor 1 (EGLN1) in the genetic mechanisms underlying this adaptation ...
Yunden Droma, Fengming Yue, Masao Ota, Nobumitsu Kobayashi, Yoshiaki Kitaguchi, Masayuki Hanaoka   +5 more
wiley   +1 more source

Multiple Mammalian Cytokines and Erythropoietin-Mimetic Peptides Protect Insect Neurons via Phylogenetically Conserved Cytokine Receptor-Like Factor 3 (CRLF3). [PDF]

J Neurochem
Hahn N, Knorr DY, Twellsieck B, Huang R, Trebilcock A, Schwedhelm-Domeyer N, Pauls S, Werven LV, Jahn O, Ehrenreich H, Heinrich R.   +10 more
europepmc   +1 more source

Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T‐cell receptor beta motif

British Journal of Haematology, Volume 208, Issue 5, Page 1797-1805, May 2026.
Summary T‐cell abnormalities have been implicated in the pathogenesis of acquired pure red cell aplasia (PRCA), particularly in its major subtypes such as idiopathic PRCA, thymoma‐associated PRCA and large granular lymphocytic leukaemia (LGLL)–associated PRCA, and the precise details remain unclear.
Naruaki Yamashita, Toru Kawakami, Shuji Matsuzawa, Shotaro Miyairi, Masae Maruyama, Fumihiro Kawakami, Shunsuke Kojima, Ryu Yanagisawa, Yumiko Higuchi, Hideki Makishima, Hideyuki Nakazawa, Fumihiro Ishida   +11 more
wiley   +1 more source

Anemia of Critical Illness: A Concise Definitive Review in Critical Care. [PDF]

Crit Care Med
Corwin HL, Napolitano LM.
europepmc   +1 more source

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4205-4215, May 2026.
ABSTRACT Aims Treatment options for post‐bariatric hypoglycaemia (PBH) are empirical. We aimed to investigate the efficacy and safety of acarbose and canagliflozin for the treatment of PBH. Materials and Methods We performed a randomised, double‐blinded, cross‐over, placebo‐controlled clinical trial where placebo, acarbose 50 mg thrice daily, and ...
Carolina B. Lobato, Clara Tornøe Winding, Kirstine N. Bojsen‐Møller, Bolette Hartmann, Christoffer Martinussen, Simon Veedfald, Jens J. Holst, Sten Madsbad, Nils Bruun Jørgensen, Carsten Dirksen   +9 more
wiley   +1 more source

Therapeutic and biomarker potential of erythropoietin in neurodegenerative diseases: a systematic review. [PDF]

BMC Neurol
Babazadeh M, Sanaie S, Rahnemayan S.
europepmc   +1 more source

Iron Status, Erythropoietin, and Cancer Incidence in the General Population

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
This study investigated the association between iron parameters and EPO and the development of overall and site‐specific cancer in a large cohort with a median follow‐up of 18.5 years (n = 6109; 1090 de novo malignancies). In multivariable cox proportional hazard analysis, we found that increased EPO, and decreased hepcidin concentrations are ...
Siem J. van Alfen, Pien Rawee, Li Luo, Ilja M. Nolte, Bert van der Vegt, Jenny E. Kootstra‐Ros, Stephan J. L. Bakker, Ron T. Gansevoort, Thera P. Links, Wouter T. Zandee, Michele F. Eisenga   +10 more
wiley   +1 more source

Two Cases of Giant Uterine Leiomyomas With Myomatous Erythrocytosis Syndrome Treated by Laparoscopic Hysterectomy. [PDF]

Cureus
Aimoto N, Matsumoto T, Tsuda Y, Yumi H.
europepmc   +1 more source